SHP099

SHP099 is a highly potent, selective, orally bioavailable small-molecule allosteric inhibitor of the protein tyrosine phosphatase SHP2 (PTPN11), originally described by Novartis collaborators as a tool compound for targeting SHP2-driven oncogenic signaling.[7][13] By binding at the interface of the N‑terminal SH2, C‑terminal SH2, and catalytic phosphatase domains, SHP099 stabilizes SHP2 in its autoinhibited conformation, thereby blocking its phosphatase activity, suppressing RAS–RAF–MEK–ERK and related RTK-driven pathways, and inhibiting proliferation of receptor–tyrosine–kinase–dependent tumor cells in preclinical models.[7][1][9] SHP099 demonstrates antitumor activity across multiple xenograft models, modulates both tumor cell signaling and the tumor immune microenvironment, enhances CD8+ T‑cell–mediated antitumor immunity, and synergizes preclinically with agents such as PD‑1 checkpoint inhibitors, MEK/PI3K inhibitors, and BRAF inhibitors.[2][4][5][9] Beyond oncology, SHP099 has been investigated preclinically in inflammatory and osteoclast-mediated conditions, including acute lung injury, sepsis, growth plate injury, and Sjögren’s-like disease, where SHP2 inhibition reduces inflammatory cytokine production and osteoclastogenesis.[3][6][11]